Opioid REMS Resource: Tools for Safe Prescribing in Chronic Pain Management

Program Overview


This educational supplement has been created to educate healthcare professionals on the safe and proper use of Extended Release (ER) and Long Acting (LA) opioids for chronic pain management. Opioids are the cornerstone of modern pain management. They are highly complex molecules which require knowledge and integration of basic science,clinical, pharmacological, psychosocial, abuse, diversion, and public health aspects of opioids. This Opioid Risk Evaluation and Mitigation Strategy (REMS) supplement is a valuable tool that can be utilized daily by everyone in your practice. Continuing Medical Education (CME/CE) credits are available for studying this supplement and completing the online test. The supplement and test can be completed in a little more than three hours, but it will have a lifetime benefit!

Target Audience

The target audience includes all clinicians registered with the DEA, eligible to prescribe schedule 2 or 3 drugs that have written at least one ER/LA opioid prescription in the past year, including primary care (family practice and internal medicine); anesthesiology (including pain management); oncology; neurology; orthopedics; PM&R and palliative care physicians, physician assistants and nurse practitioners. Pharmacists would also benefit from this education.

Program Overview

This monograph will evaluate clinical guidelines for the use of opioids, including the FDA Opioid REMS requirements, and their impact on the management of chronic pain. This monograph will also evaluate recommended opioid risk-reduction strategies HCPs can use to detect opioid misuse in a timely manner. Finally, the monograph will identify communication strategies HCPs can use to improve their relationships with their patients to ensure optimal patient outcomes and reduce the risk of opioid misuse and abuse.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Utilize available screening tools for the effective assessment of patients before initiating opioid therapy (Blueprint sections I and II)

  2. Implement opioid risk-reduction strategies based on a patient’s aberrant behavior (Blueprint sections I and II)

  3. Apply communication strategies to strengthen relationships with patients and improve patient knowledge of their opioid treatment (Blueprint sections III and IV)

  4. Properly monitor patients on opioid therapy utilizing available resources, including Patient-Provider Agreements and state Prescription Drug Monitoring Programs (Blueprint sections III and IV)

  5. Identify potential adverse events in patients on opioid therapy (Blueprint sections V and VI)

  6. Mitigate drug-drug interactions with patients on opioid therapy(Blueprint sections V and VI)


Paul A. Sloan, MD
Department of Anesthesiology
University of Kentucky Medical Center
Lexington, Kentucky

Mellar P. Davis, MD, FCCP
Department of Solid Tumor Oncology
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio

Pamel Gamier, RN, BSN, CHPN
Department of Solid Tumor Oncology
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) and Dannemiller that any person who is in a position to control the content of a CME/CE activity must disclose all relevant financial relationships they have with a commercial interest. The faculty and non-faculty reported the following regarding financial relationships that they or their spouse/life partners have or do not have with commercial interests:

Faculty Relationship Identified With

Paul A. Sloan, MD

Consultant/Advisor: Mallinckrodt Pharmaceuticals.

Mellar P. Davis, MD, FCCP

Research Grant: Pfizer, Inc.

Pamela Gamier, RN, BSN, CHPN

Has disclosed no relevant financial relationships.

Non-faculty: Perry Fine, MD, content reviewer disclosed that he is a consultant/advisor for kaléo, Inc.; Pfizer, Inc.; Zogenix, Inc., and Magellan Health, Inc. All others, including their spouse/life partners, have no financial relationships to report: Bernard Abrams, MD, Dannemiller Medical Director, content reviewer; Sandy Breslow; Richard DeVito, Jr.; Brynne Hunter and Michelle Montgomery; Elsevier, Dannemiller and Journal of Opioid Management staff.

Co-provided by Elsevier Office of Continuing Medical Education and Dannemiller, Inc. in collaboration with Journal of Opioid Management.

Commericial Support

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies.

Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the Food & Drug Administration.

Accreditation Statement

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 3.0 AMA PRA Category 1CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 3 hours of continuing education which includes 1 hour of pharmacology.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabled Use: This educational activity may contain discussion of publishedand/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, Dannemiler, Inc., Journal of Opioid Management and ER/LA Opioid Analgesic REMS Program Companies do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

Privacy Policy

Course details

  • Course opens: March 19, 2015
  • Course expires: September 19, 2016

This activity closed on September 19th, 2016 and is no longer available for enrollments.